Global Neuromyelitis Optica Treatment Market, By Types (Neuromyelitis Optica Spectrum Disorder with Aquaporin-4 Antibodies, Neuromyelitis Optica Spectrum Disorder without Aquaporin-4 Antibodies), Treatment Type (Medication, Plasma Exchange Therapy, Immunoglobulin Therapy), Drugs (C5 Protein Inhibitor, Oral Corticosteroid, Non-Steroid Immunosuppressive Drugs, and Others), Route of Administration(Oral and Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028